A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer

The aim of this study was to determine the maximum-tolerated dose (MTD), the dose-limiting toxicity (DLT) and the recommended dose (RD) of neoadjuvant chemotherapy (NAC) with gemcitabine (GEM) plus oral S-1 in patients with resectable pancreatic cancer. Thirteen patients with radiologically proven r...

Descripción completa

Detalles Bibliográficos
Autores principales: TAJIMA, HIDEHIRO, KITAGAWA, HIROHISA, TSUKADA, TOMOYA, NAKANUMA, SHINICH, OKAMOTO, KOICHI, SAKAI, SEISHO, MAKINO, ISAMU, FURUKAWA, HIROYUKI, NAKAMURA, KEISHI, HAYASHI, HIRONORI, OYAMA, KATSUNOBU, INOKUCHI, MASAFUMI, NAKAGAWARA, HISATOSHI, MIYASHITA, TOMOHARU, FUJITA, HIDETO, ITOH, HIROSHI, TAKAMURA, HIROYUKI, NINOMIYA, ITASU, FUSHIDA, SACHIO, FUJIMURA, TAKASHI, OHTA, TETSUO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915328/
https://www.ncbi.nlm.nih.gov/pubmed/24649244
http://dx.doi.org/10.3892/mco.2013.133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915328/
https://www.ncbi.nlm.nih.gov/pubmed/24649244
http://dx.doi.org/10.3892/mco.2013.133

Ejemplares similares